Psychiatry AtlasMedication guide · United States

Sleep medicine that blocks wakefulness signals

Suvorexant (Belsomra)

Generic name
suvorexant
Brand names
Belsomra
Medication class
Sleep medicine that blocks wakefulness signals
Forms covered
oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Suvorexant (Belsomra) treats adult insomnia involving difficulty falling asleep, staying asleep, or both. It can also impair alertness the next day, even when taken as prescribed.

What to expect: The goal is easier sleep onset or less time awake during the night, without unsafe daytime sleepiness.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Insomnia with difficulty falling asleep and/or staying asleep — Adults; pediatric safety and effectiveness are not established. This is the Belsomra oral tablet indication. Persistent insomnia needs evaluation for other medical, sleep or mental health conditions.oral tablets.

What should I expect?

The goal is easier sleep onset or less time awake during the night, without unsafe daytime sleepiness. Contact the prescriber if insomnia does not improve within 7 to 10 days, or if it worsens, because other causes of sleep trouble may need attention.

How do I take it safely?

Take only the prescribed dose, no more than once a night, within 30 minutes of bedtime and with at least seven hours before planned awakening. Food may delay the effect. Do not add another dose to force sleep.

Do not use with narcolepsy. Review sleep apnea or other breathing disease, depression, falls, substance use, and liver disease. Severe liver impairment or strong interacting medicines can make treatment unsuitable. Avoid driving if sleepy or not fully alert the next day.

Strong CYP3A inhibitors, such as ketoconazole or clarithromycin, can markedly increase suvorexant exposure and are not recommended with it. Moderate inhibitors such as diltiazem require dose adjustment; strong inducers such as rifampin can reduce its effect. Alcohol, opioids, benzodiazepines and other sedatives add to impairment. The label advises against combining Belsomra with other insomnia medicines. It can increase digoxin levels, so digoxin concentrations need monitoring when used together.

Human pregnancy data are insufficient to determine drug-associated risks. The 2025 label reports low concentrations of suvorexant and its metabolite in human milk; infant outcome and milk-production data remain absent, so low transfer does not prove safety. Discuss feeding and treatment together. Pediatric safety and efficacy are not established. Older adults are especially vulnerable to falls from drowsiness, even though trial averages did not show a major age-related difference at recommended doses.

Take it only when a full night remains. Do not take an extra dose during the same night to make up for a missed dose or to force sleep. If fewer than seven hours remain before planned awakening, skip it and follow the prescriber’s instructions.

Trials did not show a clear withdrawal syndrome after discontinuation, but this controlled medicine still has abuse potential; discuss ongoing need and stopping with the prescriber. Stop and seek advice immediately after a complex sleep behavior.

What side effects should I know about?

  • Excessive sleepiness or next-day drowsiness.
  • Headache, dizziness or unusual dreams can occur.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Sleep-driving, sleepwalking or other activities while not fully awake: stop the medicine and contact the prescriber immediately.
  • Suicidal thoughts or new major behavioral changes need immediate assessment.
  • Trouble breathing, collapse or inability to awaken requires emergency care.
  • Tell the prescriber promptly about being unable to move when falling asleep or waking, vivid dream-like experiences while awake, or sudden muscle weakness; these are recognized effects of this medicine.

What else should I know to stay safe?

  • Do not use with narcolepsy. Review sleep apnea or other breathing disease, depression, falls, substance use, and liver disease; severe liver impairment makes use unsuitable. Human pregnancy information is limited, and low amounts in milk do not establish infant safety. Pediatric effectiveness is not established.
  • Avoid alcohol and adding another insomnia medicine. Opioids, benzodiazepines, and other sedatives add impairment; strong CYP3A inhibitors are not recommended, other inhibitors may require adjustment, and digoxin can need blood-level monitoring. Have the full medicine list checked.
  • Allow at least seven hours before planned waking and never add another dose during the same night. Next-day driving can remain impaired despite a full night’s sleep; older adults are especially vulnerable to falls. Review persistent insomnia and ongoing need with the prescriber.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Taking it after a meal may delay the effect. Do not respond by adding another dose during the night.
  • Allowing seven hours for sleep does not guarantee that driving is safe the next morning. Notice daytime alertness and follow the product’s driving precautions.

How does it work?

Suvorexant reduces a signal that helps the brain stay awake. It blocks the action of orexin, a chemical messenger involved in maintaining wakefulness, so the pressure to stay awake can lessen and sleep can become easier. This action does not mean that everyone with insomnia has too much orexin.

Explore medication science

How was this medicine developed?

The FDA approved Belsomra in 2014. Suvorexant introduced an insomnia treatment that blocks orexin, a messenger that helps sustain wakefulness. Its clinical evaluation included both nighttime sleep and next-day driving effects.

How do I say the name?

Suvorexant: soo-voh-REX-ant. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Suvorexant: current product prescribing information
  2. Suvorexant: patient medicine information
  3. Suvorexant: original product approval and regulatory history
  4. Belsomra: Package Insert / Prescribing Information / MOA
  5. Suvorexant: verified parent compound, PubChem CID 24965990
  6. Ativan oral tablet prescribing information

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top